Advertisement
EXEL vs HRMY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a Buy and HRMY is a Hold.
EXEL in +4.41% Uptrend, rising for three consecutive days on November 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where EXEL advanced for three days, in 209 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for EXEL just turned positive on October 09, 2026. Looking at past instances where EXEL's MACD turned positive, the stock continued to rise in 29 of 43 cases over the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 172 of 274 cases where EXEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
Bearish Trend Analysis
The 10-day RSI Indicator for EXEL moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In 24 of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at 60%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 75 cases where EXEL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
EXEL broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 23 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. EXEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.349) is normal, around the industry mean (3.498). P/E Ratio (21.146) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (2.618) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (6.305) is also within normal values, averaging (440.869).
HRMY in downward trend: 10-day moving average moved below 50-day moving average on October 08, 2026
The 10-day moving average for HRMY crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HRMY as a result. In 69 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for HRMY turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 32 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
HRMY moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for HRMY entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HRMY's RSI Indicator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where HRMY advanced for three days, in 206 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
HRMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 38 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. HRMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.930) is normal, around the industry mean (3.498). P/E Ratio (10.578) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.581) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
EXEL | HRMY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 40 | 62 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 81 Overvalued | |
PROFIT vs RISK RATING 1..100 | 3 | 100 | |
SMR RATING 1..100 | 23 | 46 | |
PRICE GROWTH RATING 1..100 | 36 | 61 | |
P/E GROWTH RATING 1..100 | 20 | 38 | |
SEASONALITY SCORE 1..100 | 15 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
HRMY's Valuation (81) in the null industry is in the same range as EXEL (90) in the Biotechnology industry. This means that HRMY’s stock grew similarly to EXEL’s over the last 12 months.
EXEL's Profit vs Risk Rating (3) in the Biotechnology industry is significantly better than the same rating for HRMY (100) in the null industry. This means that EXEL’s stock grew significantly faster than HRMY’s over the last 12 months.
EXEL's SMR Rating (23) in the Biotechnology industry is in the same range as HRMY (46) in the null industry. This means that EXEL’s stock grew similarly to HRMY’s over the last 12 months.
EXEL's Price Growth Rating (36) in the Biotechnology industry is in the same range as HRMY (61) in the null industry. This means that EXEL’s stock grew similarly to HRMY’s over the last 12 months.
EXEL's P/E Growth Rating (20) in the Biotechnology industry is in the same range as HRMY (38) in the null industry. This means that EXEL’s stock grew similarly to HRMY’s over the last 12 months.
| EXEL | HRMY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 60% | 2 days ago 77% |
| Stochastic ODDS (%) | 2 days ago 52% | 2 days ago 75% |
| Momentum ODDS (%) | N/A | 2 days ago 78% |
| MACD ODDS (%) | 2 days ago 67% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 57% | 2 days ago 71% |
| TrendMonth ODDS (%) | 2 days ago 67% | 2 days ago 72% |
| Advances ODDS (%) | 3 days ago 68% | 3 days ago 73% |
| Declines ODDS (%) | about 1 month ago 59% | 7 days ago 74% |
| BollingerBands ODDS (%) | 2 days ago 61% | 2 days ago 69% |
| Aroon ODDS (%) | 2 days ago 63% | 2 days ago 74% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EXEL’s FA Score shows that 3 FA rating(s) are green while HRMY’s FA Score has 0 green FA rating(s).
- EXEL’s FA Score: 3 green, 2 red.
- HRMY’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EXEL’s TA Score shows that 3 TA indicator(s) are bullish while HRMY’s TA Score has 4 bullish TA indicator(s).
- EXEL’s TA Score: 3 bullish, 4 bearish.
- HRMY’s TA Score: 4 bullish, 6 bearish.
Price Growth
EXEL (@Biotechnology) experienced а -2.39% price change this week, while HRMY (@Biotechnology) price change was -9.37% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
EXEL is expected to report earnings on Feb 09, 2027.
HRMY is expected to report earnings on Mar 02, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
HRMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, HRMY has been loosely correlated with SNDX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if HRMY jumps, then SNDX could also see price increases.
| Ticker / NAME | Correlation To HRMY | 1D Price Change % | ||
|---|---|---|---|---|
| HRMY | 100% | -0.68% | ||
| SNDX - HRMY | 36% Loosely correlated | -0.63% | ||
| KURA - HRMY | 35% Loosely correlated | N/A | ||
| EXEL - HRMY | 34% Loosely correlated | -1.62% | ||
| KROS - HRMY | 34% Loosely correlated | +1.74% | ||
| RXRX - HRMY | 33% Loosely correlated | -6.70% | ||
More | ||||